Trials / Completed
CompletedNCT07013760
Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
Observational Retrospective Study to Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 420 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
Observational retrospective study to characterize and assess clinical outcomes of patients receiving tezepelumab after marketing approval in Spain
Detailed description
T-ROSS-II has been designed to conduct a new observational study to generate additional evidence on the use of tezepelumab in severe asthma patients in routine clinical practice in Spain after its launch. This is an observational, multi-centre, retrospective, single-arm study in patients 12 years and older with severe asthma. Approximately 400 patients meeting the study eligibility criteria will be included in the T-ROSS-II.
Conditions
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2025-12-19
- Completion
- 2025-12-19
- First posted
- 2025-06-10
- Last updated
- 2026-01-12
Locations
12 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT07013760. Inclusion in this directory is not an endorsement.